Literature DB >> 15319034

Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy.

Goufeng Zhang1, James J Ludtke, Christine Thioudellet, Patricia Kleinpeter, Michael Antoniou, Hans Herweijer, Serge Braun, Jon A Wolff.   

Abstract

Our previous studies have demonstrated that the intraarterial delivery of naked plasmid DNA leads to high levels of foreign gene expression throughout the muscles of the targeted limb. Although the procedure was first developed in rats and then extended to nonhuman primates, the present study has successfully implemented the procedure in normal mice and the mdx mouse model for Duchenne muscular dystrophy. After intraarterial delivery of plasmid DNA expressing the normal, full-length mouse dystrophin from either the cytomegalovirus promoter or a muscle-specific human desmin gene control region, mdx mouse muscle stably expressed dystrophin in 1-5% of the myofibers of the injected hind limb for at least 6 months. This expression generated an antibody response but no apparent cellular response. Copryright Mary Ann Liebert, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319034     DOI: 10.1089/1043034041648408

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  22 in total

1.  High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.

Authors:  Xiu-Hua Peng; Xiao-Nan Ren; Li-Xiang Chen; Bi-Sheng Shi; Chun-Hua Xu; Zhong Fang; Xue Liu; Jie-Liang Chen; Xiao-Nan Zhang; Yun-Wen Hu; Xiao-Hui Zhou
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

Review 3.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

4.  Progress toward a nonviral gene therapy protocol for the treatment of anemia.

Authors:  Magdolna G Sebestyén; Julia O Hegge; Mark A Noble; David L Lewis; Hans Herweijer; Jon A Wolff
Journal:  Hum Gene Ther       Date:  2007-03       Impact factor: 5.695

Review 5.  Delivery of Adeno-Associated Virus Gene Therapy by Intravascular Limb Infusion Methods.

Authors:  Alisha M Gruntman; Terence R Flotte
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09-10       Impact factor: 5.032

6.  In Situ Transfection by Controlled Release of Lipoplexes Using Acoustic Droplet Vaporization.

Authors:  Benjamin A Juliar; Melissa M Bromley; Alexander Moncion; Denise C Jones; Eric G O'Neill; Christopher G Wilson; Renny T Franceschi; Mario L Fabiilli
Journal:  Adv Healthc Mater       Date:  2016-05-18       Impact factor: 9.933

7.  Desmin-regulated lentiviral vectors for skeletal muscle gene transfer.

Authors:  Gillian E Talbot; Simon N Waddington; Olivia Bales; Rose C Tchen; Michael N Antoniou
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 8.  Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.

Authors:  Abdallah Fayssoil; Olivier Nardi; David Orlikowski; Djillali Annane
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

9.  Synthesis and evaluation of amphiphilic poly(tetrahydrofuran-b-ethylene oxide) copolymers for DNA delivery into skeletal muscle.

Authors:  Catherine Pomel; Christian Leborgne; Hervé Cheradame; Daniel Scherman; Antoine Kichler; Philippe Guegan
Journal:  Pharm Res       Date:  2008-09-03       Impact factor: 4.200

Review 10.  Molecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.

Authors:  Anthony Scimè; Michael A Rudnicki
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.